Catalyst Pharmaceuticals (CPRX) Announces Settlement of FIRDAPSE Patent Litigation with Teva Pharmaceuticals
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/25/2026
- Wall St edges up on AI enthusiasm, Mideast negotiation hopes
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices drop about 3% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- S&P 500 ends marginally lower as investors focus on US-Iran war
Oppenheimer on Catalyst Pharmaceutical (CPRX): 'We believe that uncertainty around this topic had kept many on the sidelines and that today's update will facilitate investor interest'
January 8, 2025 3:06 PM ESTOppenheimer analyst Leland Gershell reiterated an Outperform rating and $29.00 price target on Catalyst Pharmaceutical Partners (NASDAQ: CPRX).
The analyst comments "Earlier today CPRX announced that it has broadly settled with Paragraph 4 challenger TEVA, by which TEVA has agreed to not market a generic... More
BofA on Catalyst Pharmaceutical (CPRX): 'Firdapse IP settlement sets favorable LOE, assuming other 2 generic filers follow suit'
January 8, 2025 3:05 PM ESTBofA Securities analyst Jason M. Gerberry reiterated a Buy rating and $30.00 price target on Catalyst Pharmaceutical Partners (NASDAQ: CPRX).
The analyst comments "Today, Catalyst Pharma (CPRX) shares are outperforming (+15% versus flat market) following announcement of a Firdapse patent settlement with a key generic challenger (Teva). Teva was important as one of three shared generic Firdapse first-filers; Firdapse is CPRXs largest... More
Citi Catalyst Pharmaceutical (CPRX): 'Firdapse Patent Litigation Settlement with Teva Meaningfully Derisks LOE Overhang on Shares'
January 8, 2025 3:04 PM ESTCiti analyst Samantha Semenkow reiterated a Buy rating and $31.00 price target on Catalyst Pharmaceutical Partners (NASDAQ: CPRX)
The analyst comments "Catalyst announced they have reached a settlement with Teva regarding the Firdapse patent litigation. Per the settlement, Teva has agreed... More
